The Global Health Body Sounds Warning Over Acute Lack of Obesity Jabs
Less than one in 10 individuals that would benefit from weight-loss injections including Wegovy are able to get them, warns the global health agency as it releases its initial guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to this class of drugs.
Based on forecasts, more than two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidance acknowledges that obesity is a chronic disease that can be managed with holistic and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key hurdles to widespread access to the injections that can help people shift significant weight, says the body.
GLP-1 Therapy Supply Crisis
Even in the current most favorable case, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of eligible patients, according to the health organization.
The guideline calls on governments and firms to increase availability, via measures including licensing agreements.
The intellectual property rights on semaglutide – the core component of a leading brand – is scheduled to end in multiple nations in 2026.
How Weight-Loss Drugs Function
These medications mimick a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so people consume fewer calories.
People typically begin shedding pounds after several weeks of commencing the weekly injections.
Studies indicates people may see weight return a year later of stopping the treatment, because their typical hunger resume.
To be carrying excess weight raises your risk for contracting diseases, like diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.
